GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biofrontera AG (XTER:B8FK) » Definitions » Total Long-Term Liabilities

Biofrontera AG (XTER:B8FK) Total Long-Term Liabilities : €0.68 Mil (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Biofrontera AG Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. Biofrontera AG's Total Long-Term Liabilities for the quarter that ended in Dec. 2023 was €0.68 Mil.

Biofrontera AG Total Long-Term Liabilities Historical Data

The historical data trend for Biofrontera AG's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biofrontera AG Total Long-Term Liabilities Chart

Biofrontera AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 36.83 40.73 1.23 4.00 0.68

Biofrontera AG Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 1.28 0.95 0.85 0.68

Biofrontera AG Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.

Biofrontera AG Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Biofrontera AG's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Biofrontera AG (XTER:B8FK) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biofrontera AG (XTER:B8FK) » Definitions » Total Long-Term Liabilities
Comparable Companies
XTER:PA8 XTER:HAEK ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692 NSE:DIVISLAB BOM:500124 VTRS NBIX SZSE:000963 SHSE:600085 XPAR:IPN SHSE:600196
Traded in Other Exchanges
B8F:Germany B8F:Germany B8F:Germany
Address
Hemmelrather Weg 201, Leverkusen, NW, DEU, 51377
Website
https://www.biofrontera.com
Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin.

Biofrontera AG (XTER:B8FK) Headlines

No Headlines